N = 124 patients | |
Age (Y) | 32 ± 2.8 |
Gender (M/F) | 5 / 119 |
AN-R type | 90 (73%) |
AN-BP type | 34 (27%) |
Duration of AN since diagnostic (Y) | 7.9 ± 5.7 |
BMI | 12.3 ± 2,5 |
HR (bpm) | 61.6 ± 17.2 |
SBP (mm Hg) | 99.2 ± 12 |
DBP (mmHg) | 65.6 ± 10.6 |
Body composition (DEXA) | |
FFM (Kg) | 28.8 ± 4.8 |
FM (%) | 8.8 ± 3.8 |
FFMI (%) | 10.8 ± 1.4 |
Cardiac findings | |
QT interval (mm) | 406 ± 54 |
QTc interval (mm) | 385 ± 31 |
QT/QTc | 1 ± 0.1 |
Pericardial effusion | 34 (27%) |
LVEF (%) | 63 ± 10 |
LV mass (g) | 80 ± 22 |
Biological findings | |
Albumin (38–52 g/l) | 36.9 ± 7.1 |
Transthyretin (0.21–0.45 g/l) | 0.248 ± 0.102 |
CRP (< 5 mg/l) | 6.5 ± 23.7 |
BNP (< 100 pg /l) | 54 ± 70 |
Potassium (3.7–4.7 mmol/l) | 3.8 ± 0.6 |
Calcium (2.12–2.52 mmol/l) | 2.2 ± 0.1 |
Phosphorus (0.8–1.45 mmol/l) | 1.1 ± 0.3 |
Magnesium (0.70–1.00 mmol/l) | 0.8 ± 0,1 |
Patients with Hypertransaminasemiaa | 34 (27%) |
AST (15–37 UI/l) | 137.6 ± 425.8 |
ALT (12–78 UI/l) | 170.1 ± 371.4 |
Total Cholesterol (C) (3.00–6.00 mmol/l) | 4.2 ± 1.4 |
HDL-C (0.8–1.9 mmol/l) | 1.8 ± 0.7 |
LDL-C (< 4.1 mmol/l) | 2.1 ± 1.1 |
Total TG (< 1.7 mmol/l) | 0.9 ± 0.7 |